Darobactin (Antibiotic from Photorhabdus)

**Darobactin** is a novel ribosomally-synthesized and post-translationally modified peptide (RiPP) antibiotic isolated from Photorhabdus luminescens and related species, first reported in a 2019 Nature paper by Imai et al. (Lewis lab, Northeastern University). It is the first entirely new structural class of antibiotic effective against gram-negative bacteria in over 50 years. ## Why it matters Gram-negative bacteria — including clinically important pathogens like *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Enterobacter cloacae* — have an outer membrane that acts as a barrier to most antibiotics. The ESKAPE pathogens (responsible for most hospital-acquired drug-resistant infections) are dominated by gram-negatives, and new options have been scarce. Existing gram-negative antibiotic classes (beta-lactams, aminoglycosides, fluoroquinolones, polymyxins, tetracyclines) are all 50+ years old. Resistance has accumulated across all of them. Darobactin is a structurally novel class where pre-existing resistance mechanisms don't apply. ## Mechanism Darobactin binds **BamA**, the essential outer-membrane protein-folding chaperone. All gram-negative bacteria need BamA to correctly insert proteins into their outer membrane. Binding BamA prevents outer-membrane assembly; bacteria can't maintain the membrane barrier, can't properly secrete virulence factors, and die. This is a novel target. Most prior antibiotics target cell wall synthesis (beta-lactams), ribosomes (tetracyclines, aminoglycosides), DNA replication (fluoroquinolones), or folate (sulfonamides). Hitting an outer-membrane assembly chaperone is a new axis, and evolving resistance requires non-trivial modifications to an essential protein. ## Discovery method The discovery process is itself interesting. Darobactin's biosynthetic operon is **silent** in Photorhabdus under standard lab culture conditions — standard antibiotic screening would never have found it. The Lewis lab used a targeted activation approach: inducing expression of dormant biosynthetic gene clusters in Photorhabdus to 'wake up' unknown potential products. Implication: soil bacteria likely contain **hundreds of unknown antibiotic classes** in silent operons. The 1990s-2000s 'the antibiotic pipeline is dry' narrative was more about screening methodology than about biological scarcity. Modern genomic tools are unlocking the silent half of the biosynthetic space. ## Clinical development - Total chemical synthesis achieved 2020-2023, enabling industrial production and analogue development. - Preclinical animal infection models show activity against clinical MDR isolates. - Analogue programs are producing candidates with improved pharmacokinetics. - As of 2026, clinical trials are in progress. No FDA approval yet. ## Relation to Photorhabdus biology Photorhabdus luminescens naturally produces a small arsenal of antibiotics to kill competing microbes when digesting insect hosts. Darobactin is one of several. Others include darobactins B-E (natural analogues), stilbene derivatives, and protease inhibitors. This makes Photorhabdus a rich discovery platform for related chemistry. See Angel's Glow at Shiloh for the historical route by which Photorhabdus came to medical attention — Civil War folklore solved by high-school students in 2001, leading to 2019 antibiotic discovery. The full chain from 1862 observation to 2026 clinical trials is ~164 years. ## Broader significance Darobactin is a case study in what modern antibiotic discovery looks like: - Genomic mining of silent biosynthetic gene clusters. - Cross-kingdom leverage (bacterium that hunts insects produces a gram-negative antibiotic useful for humans). - Novel targets with structurally-informed design. - Total synthesis enabling analogue libraries. Compare with the 1928-1944 penicillin pipeline: random contamination + serendipity + industrial fermentation. The toolkit has changed dramatically, and the 'all antibiotics are discovered' pessimism of the 2000s looks increasingly wrong.